Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Pediatr Nephrol ; 37(2): 403-414, 2022 02.
Article in English | MEDLINE | ID: mdl-34297188

ABSTRACT

BACKGROUND: Chronic kidney disease (CKD) still leads to high mortality rates, mainly due to cardiovascular disease. One important influencing factor is persisting low-grade chronic inflammation partly maintained by gingivitis that favors transient bacteremia during daily activities such as toothbrushing. METHODS: To examine whether intensive dental prophylaxis can restore oral health, reduce the prevalence of bacteremia and degree of systemic inflammation indicated by CRP levels, we conducted this pilot study examining 30 CKD patients aged 6-26 years, 15 receiving intensive prophylaxis (IP), 15 receiving treatment as usual (TAU) serving as control group. There were three appointments for examination, each 10 ± 1 weeks apart (at baseline, after intervention periods one and two, when TAU also received IP, and the IP group stopped prophylaxis). RESULTS: The gingival index (GI) in the IP group decreased by 90% (GI 0.09; p=0.001), resulting in almost healthy gingiva. There was no significant change in CRP or prevalence of bacteremia. General prevalence of bacteremia after toothbrushing was 9.5% affecting 7 (26%) of the participants. In three participants, bacteremia dissolved after IP, in one after TAU. Two patients developed bacteremia ≥ 10 weeks after ending IP. We identified eight different bacterial species. CONCLUSIONS: We were able to show that IP can effectively treat gingivitis. It might be a promising approach to reduce systemic inflammation and subsequently lower premature cardiovascular disease, despite the lack of statistical significance. Future research requires a larger patient cohort to enable matched treatment groups with long-term follow-up and molecular detection methods for bacteremia. A higher resolution version of the Graphical abstract is available as Supplementary information.


Subject(s)
Bacteremia , Cardiovascular Diseases , Gingivitis , Renal Insufficiency, Chronic , Adolescent , Bacteremia/epidemiology , Bacteremia/etiology , Bacteremia/prevention & control , Child , Dental Prophylaxis , Female , Gingivitis/epidemiology , Gingivitis/etiology , Gingivitis/prevention & control , Humans , Male , Pilot Projects , Renal Insufficiency, Chronic/complications , Toothbrushing/methods , Young Adult
2.
J Neurooncol ; 124(3): 373-83, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26224160

ABSTRACT

Platelet-derived growth factor receptor (PDGFR) signaling plays an important role in the biology of malignant gliomas. To investigate mechanisms modulating PDGFR signaling in gliomagenesis, we employed a Drosophila glioma model and genetic screen to identify genes interacting with Pvr, the fly homolog of PDGFRs. Glial expression of constitutively activated Pvr (λPvr) led to glial over migration and lethality at late larval stage. Among 3316 dsRNA strains crossed against the tester strain, 128 genes shifted lethality to pupal stage, including tetraspanin 2A (tsp2A). In a second step knockdown of all Drosophila tetraspanins was investigated. Of all tetraspanin dsRNA strains only knockdown of tsp2A partially rescued the Pvr-induced phenotype. Human CD9 (TSPAN29/MRP-1), a close homolog of tsp2A, was found to be expressed in glioma cell lines A172 and U343MG as well as in the majority of glioblastoma samples (16/22, 73 %). Furthermore, in situ proximity ligation assay revealed close association of CD9 with PDGFR α and ß. In U343MG cells, knockdown of CD9 blocked PDGF-BB stimulated migration. In conclusion, modulation of PDGFR signaling by CD9 is evolutionarily conserved from Drosophila glia to human glioma and plays a role in glia migration.


Subject(s)
Cell Movement/physiology , Glioma/pathology , Neuroglia/metabolism , Receptors, Platelet-Derived Growth Factor/metabolism , Tetraspanin 29/metabolism , Analysis of Variance , Animals , Animals, Genetically Modified , Biological Evolution , Brain Neoplasms/genetics , Brain Neoplasms/pathology , Cell Line, Tumor , Cell Movement/drug effects , Cell Movement/genetics , Cell Survival/drug effects , Cell Survival/genetics , Dose-Response Relationship, Drug , Drosophila , Drosophila Proteins/genetics , Green Fluorescent Proteins/genetics , Green Fluorescent Proteins/metabolism , Humans , Neuroglia/pathology , RNA, Messenger/metabolism , RNA, Small Interfering/pharmacology , Receptors, Platelet-Derived Growth Factor/pharmacology , Signal Transduction
3.
Development ; 141(16): 3233-42, 2014 Aug.
Article in English | MEDLINE | ID: mdl-25063458

ABSTRACT

Cell migration is an important feature of glial cells. Here, we used the Drosophila eye disc to decipher the molecular network controlling glial migration. We stimulated glial motility by pan-glial PDGF receptor (PVR) activation and identified several genes acting downstream of PVR. Drosophila lox is a non-essential gene encoding a secreted protein that stiffens the extracellular matrix (ECM). Glial-specific knockdown of Integrin results in ECM softening. Moreover, we show that lox expression is regulated by Integrin signaling and vice versa, suggesting that a positive-feedback loop ensures a rigid ECM in the vicinity of migrating cells. The general implication of this model was tested in a mammalian glioma model, where a Lox-specific inhibitor unraveled a clear impact of ECM rigidity in glioma cell migration.


Subject(s)
Compound Eye, Arthropod/embryology , Drosophila Proteins/physiology , Drosophila melanogaster/physiology , Extracellular Matrix/physiology , Neuroglia/cytology , Protein-Lysine 6-Oxidase/physiology , Animals , Animals, Genetically Modified , Base Sequence , Cell Line, Tumor , Cell Movement , Drosophila Proteins/genetics , Drosophila melanogaster/metabolism , Extracellular Matrix/metabolism , Female , Gene Expression Regulation, Developmental , Glioblastoma/metabolism , Humans , Integrins/metabolism , Mice , Mice, Nude , Molecular Sequence Data , Neoplasm Transplantation , Protein-Lysine 6-Oxidase/genetics , Signal Transduction
4.
Neoplasia ; 11(9): 882-8, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19724682

ABSTRACT

Glioblastoma is the most common and most malignant intrinsic human brain tumor, characterized by extensive invasion and proliferation of glial (astrocytic) tumor cells, frequent activation of tyrosine kinase receptor signaling pathways, relative resistance to chemotherapy and radiotherapy, and poor prognosis. Using the Gal4-UAS system, we have produced glioma models in Drosophila by overexpressing homologs of human tyrosine kinase receptors under control of the glia-specific promoter reversed polarity (repo). Glial overexpression of activated epidermal growth factor receptor (EGFR) resulted in enhanced proliferation and migration of larval glial cells with increased numbers in the eye imaginal disc, diffuse tumor-like enlargement of the optic stalk, and marked ectopic invasion of glial cells along the optic nerve. Glial overexpression of the downstream kinase PI3K showed similar pathology. Overexpression of activated pvr (platelet-derived growth factor receptor/vascular endothelial growth factor receptor homolog) led to migration of glial cells along the optic nerve, whereas expression of activated htl (fibroblast growth factor receptor 1 homolog) and INR (insulin receptor) showed markedly elevated numbers of glial cells in the optic stalk. The EGFR/phosphatidylinositol 3-phosphate kinase (PI3K) phenotype was partly reverted by the administration of the EGFR tyrosine kinase inhibitor gefitinib and completely rescued by the PI3K inhibitor wortmannin and the Akt inhibitor triciribine. We suggest that Drosophila models will be useful for deciphering signaling cascades underlying abnormal behavior of glioma cells for genetic screens to reveal interacting genes involved in gliomagenesis and for experimental therapy approaches.


Subject(s)
Brain Neoplasms/metabolism , Brain Neoplasms/pathology , Drosophila melanogaster/metabolism , Glioma/pathology , Animals , Drosophila melanogaster/growth & development , ErbB Receptors/antagonists & inhibitors , ErbB Receptors/metabolism , Eye/cytology , Eye/metabolism , Gefitinib , Glioma/metabolism , Humans , Immunoenzyme Techniques , Neoplasm Invasiveness , Phosphatidylinositol 3-Kinases/metabolism , Platelet-Derived Growth Factor/metabolism , Protein Kinase Inhibitors/pharmacology , Proto-Oncogene Proteins c-akt/metabolism , Quinazolines/pharmacology , Receptors, Platelet-Derived Growth Factor/metabolism , Receptors, Vascular Endothelial Growth Factor/metabolism , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...